Page 421 - Read Online

Page 12 of 13 Shamliyan et al. Vessel Plus 2020;4:35 I http://dx.doi.org/10.20517/2574-1209.2020.34

58. Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation
2019;139:2528-36.
59. Ponikowski P. Abraham W. Favourable effects of empagliflozin on congestion, diuretic use and all-cause healthcare resource utilisation
in the EMPERIAL trials. European Society of Cardiology 365. 2020; HFA Discoveries. Available from: https://esc365.escardio.org/
Congress/223730-favourable-effects-of-empagliflozin-on-congestion-diuretic-use-and-all-cause-healthcare-resource-utilisation-in-the-
emperial-trials. [Last accessed on 16 Nov 2020]
60. Lindenfeld J. Patient-reported outcomes with empagliflozin in the EMPERIAL trials. European Society of Cardiology 365. 2020; HFA
Discoveries. Available from: https://esc365.escardio.org/Congress/223722-patient-reported-outcomes-with-empagliflozin-in-the-emperial-
trials. [Last accessed on 16 Nov 2020]
61. Boehringer Ingelheim. Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart
failure. 2019. Available from: https://wwwboehringer-ingelheimus/press-release/boehringer-ingelheim-and-lilly-provide-update-jardiance-
phase-iii-exercise-ability. [Last accessed on 16 Nov 2020]
62. Cosentino F, Cannon CP, Cherney DZI, et al. Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes
mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial. Circulation 2020; doi: 10.1161/
CIRCULATIONAHA.120.050255.
63. Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the
CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation 2018;137:323-34.
64. Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K. Effect of canagliflozin on left ventricular diastolic function
in patients with type 2 diabetes. Cardiovasc Diabetol 2018;17:73.
65. Sezai A, Sekino H, Unosawa S, Taoka M, Osaka S, Tanaka M. Canagliflozin for Japanese patients with chronic heart failure and type II
diabetes. Cardiovasc Diabetol 2019;18:76.
66. Singh JS, Fathi A, Vickneson K, et al. Research into the effect of sodium-glucose linked transporter inhibition in left ventricular
remodelling in patients with heart failure and diabetes mellitus. Eur Heart J 2018;Supplement 1(P905): American Diabetes Association
meeting, Orlando. Available from: https://esc365.escardio.org/Congress/ESC-Congress-2018/Poster-Session-1-Chronic-heart-failure-
Treatment/177516-research-into-the-effect-of-sodium-glucose-linked-transporter-inhibition-in-left-ventricular-remodelling-in-patients-
with-heart-failure-and-diabetes-mellitus. [Last accessed on 16 Nov 2020]
67. Bonora BM, Vigili de Kreutzenberg S, Avogaro A, Fadini GP. Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated
by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial. Cardiovasc
Diabetol 2019;18:106.
68. Verma S, Garg A, Yan AT, et al. Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an
important clue to the EMPA-REG outcome trial? Diabetes Care 2016;39:e212-3.
69. Cannon CP, McGuire DK, Pratley R, et al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and safety
cardiovascular outcomes trial (VERTIS-CV). Am Heart J 2018;206:11-23.
70. Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. New Engl J Med
2020;383:1425-35.
71. Sakai T, Miura S. Abstract 17041: effect of sodium-glucose cotransporter 2 inhibitor on vascular endothelial function and diastolic
function in patients with heart failure with preserved ejection fraction (hfpef). Circulation 2017;136:A17041. Available from: https://
www.ahajournals.org/doi/10.1161/circ.136.suppl_1.17041. [Last accessed on 16 Nov 2020]
72. Ejiri K, Miyoshi T, Kihara H, Hata Y, Nagano T, et al. Drug effect of luseogliflozin and voglibose on heart failure with preserved ejection
fraction in diabetic patients: a multicenter randomized-controlled trial. ESC Congress 2019. Available from: https://esc365.escardio.org/
Congress/ESC-CONGRESS-2019/New-treatment-studies-in-heart-failure/196088-drug-effect-of-luseogliflozin-and-voglibose-on-heart-
failure-with-preserved-ejection-fraction-in-diabetic-patients-a-multicenter-randomized-controlled-trial#abstract(Abstract: 1407). [Last
accessed on 16 Nov 2020]
73. U.S. Food and Drug Administration. Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors. Postmarket Drug Safety Information for
Patients and Providers 2020. Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/
sodium-glucose-cotransporter-2-sglt2-inhibitors. [Last accessed on 16 Nov 2020]
74. Ida S, Kaneko R, Imataka K, et al. Effects of oral antidiabetic drugs and glucagon-like peptide-1 receptor agonists on left ventricular
diastolic function in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. Heart Fail Rev 2020; doi:
10.1007/s10741-020-09936-w.
75. Zhang DP, Xu L, Wang LF, Wang HJ, Jiang F. Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review
and network meta-analysis. Cardiovasc Diabetol 2020;19:10.
76. Expert Panel on Cardiac Imaging, White RD, Kirsch J, Bolen MA, Batlle JC, Brown RKJ, et al. ACR Appropriateness Criteria((R))
Suspected New-Onset and Known Nonacute Heart Failure. J Am Coll Radiol 2018;15:S418-31.
77. Pieske B, Tschope C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic
algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur
heart J 2019;40:3297-317.
78. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart
failure with preserved ejection fraction. Circulation 2018;138:861-70.
79. Reddy YNV, Borlaug BA. Response by reddy and borlaug to letters regarding article, “a simple, evidence-based approach to help guide
diagnosis of heart failure with preserved ejection fraction”. Circulation 2019;139:992-3.